Clinical trialPhase 3
REMBRANDT
NCT06305559
Randomized double-blind placebo-controlled; primary endpoint percent change in total noncalcified coronary plaque volume by CCTA at 18 months.
No news refers to this card yet.
Also in the catalogue
- VICTORION-PLAQUE (inclisiran)Clinical trial
- BROADWAY (obicetrapib)Clinical trial
- ORION-4 (inclisiran)Clinical trial
- CORALreef OutcomesClinical trial
- VICTORION-2 PREVENT (inclisiran)Clinical trial
- OCEAN(a)-OutcomesClinical trial
Scales
Identifiers
- NCT
- NCT06305559
Original sources
Details
- Phase
- Phase 3
A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.